相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
Anshul Gupta et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
Harikrishna Devalapally et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport
J. Sims-Mourtada et al.
ONCOGENE (2007)
The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential
Jelmer J. van Zanden et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Modulation of function of multidrug resistance associated-proteins by Kaempferia parviflora extracts and their components
Denpong Patanasethanont et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins
Attaphol Pawarode et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells
Sung-Tsai Yu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2: HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
M. Toi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
Robert W. Robey et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells
P. Limtrakul et al.
PHYTOMEDICINE (2007)
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients
Isa E. L. M. Kuppens et al.
CLINICAL CANCER RESEARCH (2007)
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells
C. Brendel et al.
LEUKEMIA (2007)
Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer
Lilian E. van Vlerken et al.
CANCER RESEARCH (2007)
Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells
Hye Hyun Yoo et al.
PLANTA MEDICA (2007)
Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS:: Influence on ATPase activity and membrane fluidity
Eva-Maria Collnot et al.
MOLECULAR PHARMACEUTICS (2007)
Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors
Abdelhakim Ahmed-Belkacem et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Acridone derivatives: Design, synthesis, and inhibition of breast cancer resistance protein ABCG2
Ahcene Boumendjel et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells
Sylvia Mansilla et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways
X. F. Hu et al.
BRITISH JOURNAL OF CANCER (2007)
Schisandrol A from Schisandra chinensis reverses P-glycoprotein-mediated multidrug resistance by affecting Pgp-substrate complexes
Wang-Fun Fong et al.
PLANTA MEDICA (2007)
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors
Johanna Weiss et al.
DRUG METABOLISM AND DISPOSITION (2007)
Isomeric N,N-bis(cyclohexanol)amine aryl esters:: The discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors
Elisabetta Teodori et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk
Antonius E. van Herwaarden et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer
Toshiaki Saeki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dibenzocyclooctadiene lignans - A class of novel inhibitors of multidrug resistance-associated protein 1
Ling Li et al.
LIFE SCIENCES (2007)
A silent polymorphism in the MDR1 gene changes substrate specificity
Chava Kimchi-Sarfaty et al.
SCIENCE (2007)
Effects of Kaempferia parviflora extracts and their flavone constituents on P-glycoprotein function
Denpong Patanasethanont et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar. 3HCl trihydrochloride ( LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma
Franck Morschhauser et al.
LEUKEMIA & LYMPHOMA (2007)
Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody
Katalin Goda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport
Azza A. K. El-Sheikh et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
Leena Gandhi et al.
CANCER (2007)
Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer
Lan Li et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer
R. O'Connor et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties
Veronika Jekerle et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Characterization of human liver cytochrome P-450 enzymes involved in the O-demethylation of a new P-glycoprotein inhibitor HM-30181
In Bok Paek et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2007)
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Elizabeth Fox et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Haloperidol is an inhibitor but not substrate for MDR1/P-glycoprotein
Koichi Iwaki et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2006)
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Ingolf Cascorbi
PHARMACOLOGY & THERAPEUTICS (2006)
Structure-activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein
Imad Raad et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Human multidrug resistance ABCB and ABCG transporters:: Participation in a chemoimmunity defense system
Balazs Sarkadi et al.
PHYSIOLOGICAL REVIEWS (2006)
In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: Implications on hematological malignancies
Harlan Galski et al.
LEUKEMIA RESEARCH (2006)
Effect of a novel vacuolar-H+-ATPase inhibitor on cell and tumor response to camptothecins
Giovanna Petrangolini et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan
Anshul Gupta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin
Wanida Chearwae et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2
Suneet Shukla et al.
BIOCHEMISTRY (2006)
In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques
Veronika Jekerle et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Takeo Nakanishi et al.
BLOOD (2006)
Metabolites of ginsenosides as novel BCRP inhibitors
g Jin Jin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Pharmacological strategies for overcoming multidrug resistance
S. Nobili et al.
CURRENT DRUG TARGETS (2006)
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer
Joseph A. Ludwig et al.
CANCER RESEARCH (2006)
Reversal of MDR1 gene-dependent multidrug resistance using low concentration of endonuclease-prepared small interference RNA
L Li et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A high-throughput cell-based assay for inhibitors of ABCG2 activity
CJ Henrich et al.
JOURNAL OF BIOMOLECULAR SCREENING (2006)
Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1)
W Chearwae et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1
R Abdul-Ghani et al.
ONCOGENE (2006)
Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)
A Lespine et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2006)
Phase III study of PSC-833 (Valspodar) in combination with vincristine, doxorubicin, and dexamethasone (Valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) - A Trial of the Eastern Cooperative Oncology Group
WR Friedenberg et al.
CANCER (2006)
An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy
K Takara et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive, multi-drug resistant cells through its action on the p-glycoprotein pump
M Vincent
MEDICAL HYPOTHESES (2006)
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells
Axel Priebsch et al.
OLIGONUCLEOTIDES (2006)
BCRP transports dipyridamole and is inhibited by calcium channel blockers
Y Zhang et al.
PHARMACEUTICAL RESEARCH (2005)
Piperazinobenzopyranones and phenalkylaminobenzopyranones: Potent inhibitors of breast cancer resistance protein (ABCG2)
A Boumendjel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism
RB Walter et al.
BLOOD (2005)
Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro
J Weiss et al.
DRUG METABOLISM AND DISPOSITION (2005)
Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1
XF Zhou et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Liposome-encapsulated curcumin - In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
L Li et al.
CANCER (2005)
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5)
CP Wu et al.
FEBS JOURNAL (2005)
Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial
A Berruti et al.
ENDOCRINE-RELATED CANCER (2005)
Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes
CP Wu et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma
L Pusztai et al.
CANCER (2005)
Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: In vitro and in vivo studies
XF Zhou et al.
DRUG METABOLISM AND DISPOSITION (2005)
Reversal of in vitro cellular MRP1 and MRP2 mediated vincristine resistance by the flavonoid myricetin
JJ van Zanden et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Flavonoid structure-activity studies identify 6-prenyichrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2
A Ahmed-Belkacem et al.
CANCER RESEARCH (2005)
Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2)
G Merino et al.
DRUG METABOLISM AND DISPOSITION (2005)
Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata
H Morita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk
JW Jonker et al.
NATURE MEDICINE (2005)
Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine
J Jin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Role of the breast cancer resistance protein (ABCG2) in drug transport
QC Mao et al.
AAPS JOURNAL (2005)
Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine
P Pavek et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Interaction of the breast cancer resistance protein with plant polyphenols
HC Cooray et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
PJ Houghton et al.
CANCER RESEARCH (2004)
Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance
LW Fu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Synthesis and evaluation of dihydropyrroloquinolines that selectively antagonize P-glycoprotein
BD Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance
SM Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1)
ZE Sauna et al.
MOLECULAR PHARMACOLOGY (2004)
VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein
H Minderman et al.
CLINICAL CANCER RESEARCH (2004)
Pheophorbide a is a specific probe for ABCG2 function and inhibition
RW Robey et al.
CANCER RESEARCH (2004)
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice
EM Kemper et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer:: National Cancer Institute of Canada Clinical Trials Group Study MA.19
L Reyno et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Synthesis and biological evaluation of taxinine analogues as orally active multidrug resistance reversal agents in cancer
X Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate
C Wang et al.
BIOCHEMICAL PHARMACOLOGY (2004)
A new sesquiterpene-coumarin ether and a new abietane diterpene and their effects as inhibitors of p-glycoprotein
AM Madureira et al.
PLANTA MEDICA (2004)
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles:: Potential role for breast cancer resistance protein in clinical drug-drug interactions
P Breedveld et al.
CANCER RESEARCH (2004)
Kendarimide A, a novel peptide reversing P-glycoprotein-mediated multidrug resistance in tumor cells, from a marine sponge of Haliclona sp.
S Aoki et al.
TETRAHEDRON (2004)
Predicting drug sensitivity and resistance:: Profiling ABC transporter genes in cancer cells
G Szakács et al.
CANCER CELL (2004)
Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells
S Kitagawa et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Multidrug resistance reversal activity of permethyl ningalin B amide derivatives
HC Tao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract
P Limtrakul et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Effects of benzyl-, phenethyl-, and α-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport
K Hu et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2)
A Gupta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder
W Chearwae et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin
EJ Wang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance
Y Imai et al.
CANCER RESEARCH (2004)
Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression - A role for BCRP in cellular folate homeostasis
I Ifergan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A practical total synthesis of hapalosin, a 12-membered cyclic depsipeptide with multidrug resistance-reversing activity, by employing improved segment coupling and macrolactonization
C Palomo et al.
JOURNAL OF ORGANIC CHEMISTRY (2004)
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic
K Shiozawa et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme
P Krishnamurthy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
C Özvegy-Laczka et al.
MOLECULAR PHARMACOLOGY (2004)
Increased anti-P-glycoprotein activity of baicalein by alkylation on the a ring
Y Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport
SZ Zhang et al.
MOLECULAR PHARMACOLOGY (2004)
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance
F Muñoz-Martínez et al.
CANCER RESEARCH (2004)
Reversal of cancer multidrug resistance by green tea polyphenols
YY Mei et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023
H Minderman et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A
H Woehlecke et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine
N Ketabi-Kiyanvash et al.
ADDICTION BIOLOGY (2003)
P-glycoprotein: from genomics to mechanism
SV Ambudkar et al.
ONCOGENE (2003)
Sensitization of cells overexpressing multidrug-resistant proteins by Pluronic P85
EV Batrakova et al.
PHARMACEUTICAL RESEARCH (2003)
Liposome-based approaches to overcome anticancer drug resistance
C Mamot et al.
DRUG RESISTANCE UPDATES (2003)
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs
G Reid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Novel plant triterpenoid drug amooranin overcomes multidrug resistance in human leukemia and colon carcinoma cell lines
C Ramachandran et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Reversal of multidrug resistance in cancer cells by pyranocoumarins isolated from Radix Peucedani
JYC Wu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Jatrophane diterpenoids from Euphorbia mongolica as modulators of the multidrug resistance of L5128 mouse lymphoma cells
J Hohmann et al.
JOURNAL OF NATURAL PRODUCTS (2003)
Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
C Nieth et al.
FEBS LETTERS (2003)
Multidrug resistance reversal activity of key ningalin analogues
DR Soenen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport
SH Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng
CH Choi et al.
PLANTA MEDICA (2003)
Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity
BH Lee et al.
ANTI-CANCER DRUGS (2003)
Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg(3)
SW Kim et al.
BIOCHEMICAL PHARMACOLOGY (2003)
Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+T lymphoblastoid CEM cell line
ML Dupuis et al.
CHEMOTHERAPY (2003)
Localisation of breast cancer resistance protein in microvessel endothelium of human brain
HC Cooray et al.
NEUROREPORT (2002)
Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs
D Burg et al.
MOLECULAR PHARMACOLOGY (2002)
New polyoxygenated steroids exhibiting reversal of multidrug resistance from the gorgonian Isis hippuris
J Tanaka et al.
TETRAHEDRON (2002)
Reversal of P-glycoprotein-mediated multidrug resistance by 5,6,7,3′,4′-pentamethoxyflavone (sinensetin)
CH Choi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
T Hegedüs et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2002)
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918
CMF Kruijtzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933
L van Zuylen et al.
EUROPEAN JOURNAL OF CANCER (2002)
3,5-dibenzoyl-1,4-dihydropyridines:: Synthesis and MDR reversal in tumor cells
M Kawase et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2002)
Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1)
BH Norman et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance
SM Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
Estrone and 17 beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance
Y Imai et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
ABC transporters as phenotypic markers and functional regulators of stem cells
KD Bunting
STEM CELLS (2002)
Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic
AH Dantzig et al.
CURRENT MEDICINAL CHEMISTRY (2001)
The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress
J Hirrlinger et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
JW Jonker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Phase I study of CBT-1™ and Taxol® in patients with Taxol® resistant cancers
RK Oldham et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier
J Wijnholds et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
